Neuroscience trials

Parkinson’s disease (PD) is a common neurodegenerative disorder affecting approximately 2% of those over 65 years. It is characterised by problems with movement including bradykinesia, rigidity, tremor and gait dysfunction, but also causes a wide…

Multiple sclerosis is an autoimmune disease of the central nervous system in which focal lymphocytic infiltration leads to damage of myelin and axons. Initially, inflammation is transient and remyelination occurs, hence early in the disease…

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects as many as 2.5 million people worldwide and 90,000 people in the United Kingdom. It is believed to arise from the interplay of polygenic…

Multiple sclerosis is an autoimmune disease of the central nervous system, in which focal lymphocytic infiltration leads to damage of myelin and axons. Initially, inflammation is transient and remyelination occurs; hence early in the disease…

The greatest unmet need for people with multiple sclerosis is an effective therapy for the progressive phase. Current treatments suppress the damage caused by the immune system but there is only a limited window in which these can work.…

Huntington’s Disease is an autosomal-dominant cytosine-adenine-guanine (CAG) trinucleotide repeat-induced neurodegenerative disorder. The disease includes cognitive, psychiatric and motor dysfunctions. There are no known treatments to slow the…

Huntington’s disease (HD) is a progressive, genetic, neurodegenerative disorder that affects approximately 5,700 people in the UK with 5 times as many at risk of having inherited the gene. Clinical features typically emerge at the height of…